UNLABELLED: Insulin-stimulated glucose transport in skeletal muscle is thought to be effected at least partly through atypical protein kinase C isoforms (aPKCs) operating downstream of phosphatidylinositol (PI) 3-kinase and 3-phosphoinositide-dependent protein kinase-1 (PDK-1). However, relatively little is known about the activation of aPKCs in physiological conditions or insulin-resistant states. Presently, we studied aPKC activation in vastus lateralis muscles of normal chow-fed and high-fat-fed rats and after streptozotocin (STZ)-induced diabetes. In normal chow-fed rats, dose-dependent increases in aPKC activity approached maximal levels after 15-30 min of stimulation by relatively high and lower, presumably more physiological, insulin concentrations, achieved by im insulin or ip glucose administration. Insulin-induced activation of aPKCs was impaired in both high-fat-fed and STZ-diabetic rats, but, surprisingly, IRS-1-dependent and IRS-2-dependent PI 3-kinase activation was not appreciably compromised. Most interestingly, direct in vitro activation of aPKCs by PI-3,4,5-(PO(4))(3), the lipid product of PI 3-kinase, was impaired in both high-fat-fed and STZ-diabetic rats. Defects in activation of aPKCs by insulin and PI-3,4,5-(PO(4))(3) could not be explained by diminished PDK-1-dependent phosphorylation of threonine-410 in the PKC-zeta activation loop, as this phosphorylation was increased even in the absence of insulin treatment in high-fat-fed rats. CONCLUSIONS: 1) muscle aPKCs are activated at relatively low, presumably physiological, as well as higher supraphysiological, insulin concentrations; 2) aPKC activation is defective in muscles of high-fat-fed and STZ-diabetic rats; and 3) defective aPKC activation in these states is at least partly due to impaired responsiveness to PI-3,4,5-(PO(4))(3), apparently at activation steps distal to PDK-1-dependent loop phosphorylation.
UNLABELLED: Insulin-stimulated glucose transport in skeletal muscle is thought to be effected at least partly through atypical protein kinase C isoforms (aPKCs) operating downstream of phosphatidylinositol (PI) 3-kinase and 3-phosphoinositide-dependent protein kinase-1 (PDK-1). However, relatively little is known about the activation of aPKCs in physiological conditions or insulin-resistant states. Presently, we studied aPKC activation in vastus lateralis muscles of normal chow-fed and high-fat-fed rats and after streptozotocin (STZ)-induced diabetes. In normal chow-fed rats, dose-dependent increases in aPKC activity approached maximal levels after 15-30 min of stimulation by relatively high and lower, presumably more physiological, insulin concentrations, achieved by im insulin or ip glucose administration. Insulin-induced activation of aPKCs was impaired in both high-fat-fed and STZ-diabeticrats, but, surprisingly, IRS-1-dependent and IRS-2-dependent PI 3-kinase activation was not appreciably compromised. Most interestingly, direct in vitro activation of aPKCs by PI-3,4,5-(PO(4))(3), the lipid product of PI 3-kinase, was impaired in both high-fat-fed and STZ-diabeticrats. Defects in activation of aPKCs by insulin and PI-3,4,5-(PO(4))(3) could not be explained by diminished PDK-1-dependent phosphorylation of threonine-410 in the PKC-zeta activation loop, as this phosphorylation was increased even in the absence of insulin treatment in high-fat-fed rats. CONCLUSIONS: 1) muscle aPKCs are activated at relatively low, presumably physiological, as well as higher supraphysiological, insulin concentrations; 2) aPKC activation is defective in muscles of high-fat-fed and STZ-diabeticrats; and 3) defective aPKC activation in these states is at least partly due to impaired responsiveness to PI-3,4,5-(PO(4))(3), apparently at activation steps distal to PDK-1-dependent loop phosphorylation.
Authors: V Luna; L Casauban; M P Sajan; J Gomez-Daspet; J L Powe; A Miura; J Rivas; M L Standaert; R V Farese Journal: Diabetologia Date: 2006-01-05 Impact factor: 10.122
Authors: Henry J Herr; Jeffrey R Bernard; Donald W Reeder; Donato A Rivas; Jose J Limon; Ben B Yaspelkis Journal: J Physiol Date: 2005-03-31 Impact factor: 5.182
Authors: Heidi K Ortmeyer; Mini P Sajan; Atsushi Miura; Yoshinore Kanoh; Jose Rivas; Yongxiang Li; Mary L Standaert; Alice S Ryan; Noni L Bodkin; Robert V Farese; Barbara C Hansen Journal: Antioxid Redox Signal Date: 2010-11-23 Impact factor: 8.401
Authors: Mini P Sajan; Mary L Standaert; Sonali Nimal; Usha Varanasi; Tina Pastoor; Stephen Mastorides; Ursula Braun; Michael Leitges; Robert V Farese Journal: J Lipid Res Date: 2009-02-06 Impact factor: 5.922
Authors: Joshua P Thaler; Sun Ju Choi; Mini P Sajan; Kayoko Ogimoto; Hong T Nguyen; Miles Matsen; Stephen C Benoit; Brent E Wisse; Robert V Farese; Michael W Schwartz Journal: Endocrinology Date: 2009-10-09 Impact factor: 4.736
Authors: Robert V Farese; Mini P Sajan; Hong Yang; Pengfei Li; Steven Mastorides; William R Gower; Sonali Nimal; Cheol Soo Choi; Sheene Kim; Gerald I Shulman; C Ronald Kahn; Ursula Braun; Michael Leitges Journal: J Clin Invest Date: 2007-08 Impact factor: 14.808
Authors: Christian Frøsig; Mini P Sajan; Stine J Maarbjerg; Nina Brandt; Carsten Roepstorff; Jørgen F P Wojtaszewski; Bente Kiens; Robert V Farese; Erik A Richter Journal: J Physiol Date: 2007-05-31 Impact factor: 5.182